参考文献/References:
[1] Wright NT,Varney KM,Ellis KC,et al,The three-dimensional solution structure of Ca(2+)-bound S100A1 as determined by NMR spectroscopy[J].Mol Biol, 2005,353(2):410-426.
[2] Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology(including an update of the nomenclature)[J].Biochem Biophys Res Commun,2004,322(4):1111-1122.
[3] Volkers M,Rohde D,Goodman C,et al.S100A1: a regulator of striated muscle sarcoplasmic reticulum Ca2+ handling,sarcomeric, and mitochondrial function[J]. Biomed Biotechnol,2010,2010:178614.
[4] Lenarcic Zivkovic M,Zareba-Koziol M,Zhukova L,et al.Post-translational S-nitrosylation is an endogenous factor fine tuning the properties of human S100A1 protein[J].Biol Chem,2012,287(48):40457-40470.
[5] Bennett MK, Sweet WE, Baicker-McKnee S,et al. S100A1 in human heart failure: lack of recovery following left ventricular assist device support[J]. Circ Heart Fail,2014,7(4),612-618.
[6] Duarte-Costa S,Castro-Ferreira R,Neves JS,et al.S100A1: a major player in cardiovascular performance[J].Physiol Res,2014,63(6):669-681.
[7] Most P,Remppis A, Pleger ST, et al. Transgenic overexpression of the Ca2+ binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance[J].Biol Chem,2003,278(5):33809-33817.
[8] Maxwell JT,Somasuntharam I,Gray WD,et al.Bioactive nanoparticles improve calcium handling in failing cardiac myocytes[J].Nanomedicine(Lond),2015,10(22):3343-3357.
[9] Most P, Seifert H, Gao E,et al.Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction[J].Circulation,2006,114(12):1258-1268.
[10] Brinks H, Rohde D, Voelkers M,et al. S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes[J].J Am Coll Cardiol,2011,58(9): 966-973.
[11] Völkers M,Loughrey CM,Macquaide N,et al.S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes[J].Cell Calcium,2007,41(2):135-143.
[12] LeWinter MM, Granzier H. Cardiac titin: a multifunctional giant[J]. Circulation, 2010,121(19):2137-2145.
[13] Fukushima H, Chung CS, Granzier H. Titin-isoform dependence of titin-actin interaction and its regulation by S100A1/Ca2+ in skinned myocardium[J].Biomed Biotechnol,2010,2010:727239.
[14] Castro-Ferreira R, Fontes-Carvalho R, Falcao-Pires I, et al.The role of titin in the modulation of cardiac function and its pathophysiological implications[J]. Arq Bras Cardiol,2011,96(4):332-339.
[15] Rohde D,Brinks H, Ritterhoff J,et al.S100A1 gene therapy for heart failure: a novel strategy on the verge of clinical trials[J].Mol Cell Cardiol,2011,50(5):777-784.
[16] Boerries M, Most P, Gledhill JR,et al. Ca2+-dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes[J]. Mol Cell Biol,2007,27(12):4365-4373.
[17] Tsoporis JN,Mohammadzadeh F,Parker TG.S100B: a multifunctional role in cardiovascular pathophysiology[J].Amino Acids,2011,41(4):843-847.
[18] Ehlermann P,Remppis A,Guddat O,et al.Right ventricular upregulation of the Ca(2+)binding protein S100A1 in chronic pulmonary hypertension[J]. Biochim Biophys Acta,2000,1500(2): 249-255.
[19] Saraiva RM,Hare JM.Nitric oxide signaling in the cardiovascular system: implications for heart failure[J].Curr Opin Cardiol,2006,21(3):221-228.
[20] Rohde D,Busch M,Volkert A,et al.Cardiomyocytes, endothelial cells and cardiac fibroblasts: S100A1's triple action in cardiovascular pathophysiology[J]. Future Cardiol,2015,11(3):309-321.
[21] Gusev K, Ackermann GE, Heizmann CW,et al. Ca(2+)signaling in mouse cardiomyocytes with ablated S100A1 protein[J].Gen Physiol Biophys 2009,28(4):371-383.
[22] Pleger ST, Shan C, Ksienzyk J, et al.Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model[J].Sci Transl Med, 2011,3(92):92ra64.
[23] Weber C,Neacsu I,Krautz B,et al.Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model[J].Gene Ther,2014,21(2):131-138.
[24] Most P,Raake P,Weber C,et al.S100A1 gene therapy in small and large animals[J].Methods Mol Biol,2013,96(3):407-420.
[25] Rincon MY,Vanden Driessche T,Chuah MK.Gene therapy for cardiovascular disease:advances in vector development,targeting,and delivery for clinical translation[J].Cardiovasc Res,2015,108(1):4-20.
相似文献/References:
[1]赵诚,综述,朱丹,等.甲状旁腺功能减退与心脏损害[J].心血管病学进展,2016,(2):133.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.009]
ZHAO Cheng,ZHU Dan.Hypoparathyroid and Cardiac Damage[J].Advances in Cardiovascular Diseases,2016,(3):133.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.009]
[2]王振,综述,惠杰,等.迷走神经刺激与心力衰竭[J].心血管病学进展,2016,(2):197.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.026]
WANG Zhen,HUI Jie.Vagus Nerve Stimulation and Heart Failure[J].Advances in Cardiovascular Diseases,2016,(3):197.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.026]
[3]唐毅,柳志红,黄智伟,等.运动振荡呼吸在心力衰竭中的应用[J].心血管病学进展,2015,(5):551.[doi:10.3969/j.issn.1004-3934.2015.05.007]
TANG Yi,LIU Zhihong,HUANG Zhiwei,et al.Application of Exercise Oscillatory Ventilation in Heart Failure[J].Advances in Cardiovascular Diseases,2015,(3):551.[doi:10.3969/j.issn.1004-3934.2015.05.007]
[4]梅宝菲,孔一慧,李为民.睡眠障碍与心血管疾病研究新进展[J].心血管病学进展,2015,(5):603.[doi:10.3969/j.issn.1004-3934.2015.05.020]
MEI Baofei,KONG Yihui,LI Weimin.Relationship Between Somnipathy and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2015,(3):603.[doi:10.3969/j.issn.1004-3934.2015.05.020]
[5]唐光能,洪炳哲.Junctate蛋白在心力衰竭中的研究进展[J].心血管病学进展,2015,(5):629.[doi:10.3969/j.issn.1004-3934.2015.05.028]
TANG Guangneng,HONG Bingzhe.Research Development of Junctate Protein in Heart Failure[J].Advances in Cardiovascular Diseases,2015,(3):629.[doi:10.3969/j.issn.1004-3934.2015.05.028]
[6]姜琳,袁晋青.缺血性心肌病的血运重建治疗[J].心血管病学进展,2015,(6):677.[doi:10.3969/j.issn.1004-3934.2015.06.006]
JIANG Lin,YUAN Jinqing.Revascularization in Ischemic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2015,(3):677.[doi:10.3969/j.issn.1004-3934.2015.06.006]
[7]崔圆,孙宏超,侯维娜,等.生长分化因子15与心力衰竭的相关研究进展[J].心血管病学进展,2015,(6):759.[doi:10.3969/j.issn.1004-3934.2015.06.026]
CUI Yuan,SUN Hongchao,HOU Weina,et al.Research Progress on Growth Differentiation Factor-15 Associated with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(3):759.[doi:10.3969/j.issn.1004-3934.2015.06.026]
[8]秦莉 张艺文 杨晓倩 王燕凤 汪汉.系统性红斑狼疮合并心力衰竭的发病机制及病因[J].心血管病学进展,2020,(4):381.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.013]
QIN Li,ZHANG Yiwen,YANG Xiaoqian,et al.The Pathogenesis and Etiology of Heart Failure in Systemic lupus Erythematosus[J].Advances in Cardiovascular Diseases,2020,(3):381.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.013]